Bank of America Upgrades T-Mobile to Buy, Says LEO Satellite Fears Are Overdone 
Chinese Copper Foil Maker Londian Files U.S. IPO as EV Battery Demand Grows 
TetherMax Rebranding Highlights Official Exchange Partnerships as Foundation of Trust 
Tesla Q2 Deliveries Lift Chinese Auto Suppliers as EV Demand Improves 
Samsung Q2 Profit Seen Soaring as AI Memory Demand Keeps Chip Prices Elevated 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
Texas Man Charged After Fatal Tesla Full Self-Driving Crash in Katy 
Kioxia Bets on AI Memory Boom With Next-Gen NAND Production in Japan 
Kuaishou Stock Jumps as Kling AI Secures $2 Billion Funding Round 
easyJet Agrees in Principle to £5.23 Billion Castlelake Takeover Offer 
Meta Cloud Ambitions Could Challenge AWS, Azure, and Google Cloud, Says Morgan Stanley 
Lockheed Martin Emerges as Frontrunner to Acquire Ultra Maritime in $3.5 Billion Defense Deal 
ShareChat Eyes 2027 IPO After Reaching Operational Profitability, Report Says 
EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
BHP Workers Approve New Labour Agreement at WA Iron Ore Operations 
Citi Raises TSMC Price Target as AI Chip Demand Strengthens Growth Outlook 
The enormous rally in Kodak shares is expected to continue after its 318 percent increase on Wednesday on the strength of the Trump administration's announcement that will be transformed into a pharmaceutical producer and would receive a $765 million loan to launch Kodak Pharmaceuticals.
The news propelled the company's shares to a more than 200 percent jump in Tuesday trading that continued on Wednesday with the shares ending with a 318 percent increase.
The stocks climbed over 650 percent at its highest on Wednesday, prompting the New York Stock Exchange to halt trading 20 times.
Kodak, a pre-digital era giant producer of film and cameras, filed for bankruptcy in 2012 and pivoted to turn itself into a materials and chemical company.
It emerged as a restructured business in 2013.
Kodak Pharmaceuticals will produce generic active pharmaceutical ingredients to reduce America's dependency on foreign drug makers.
Kodak CEO Jim Continenza noted that since the company already manufactures essential materials for some pharmaceuticals, the new mission is only expanding that capacity.
He added that it would take around three to three and a half years to establish the new production capacity.
